Global Research on
Cardiology and Cardiovascular Diseases (GSCCD2025)
Barcelona, Spain | November 03-05, 2025
Foster Research is delighted to announce and extend a warm invitation to participants worldwide for “The Global Summit on Cardiology and Cardiovascular Diseases (GSCCD2025)”, set to take place from November 03-05, 2025, in Barcelona, Spain. The theme of the conference is "Innovative Approaches and Emerging Trends in Cardiology and Cardiovascular Health".
GRCCARDIO2025 endeavors to unite distinguished scientists, budding researchers, scholars, cardiologists, healthcare professionals, business delegates, and exceptional student communities worldwide. This conference will foster vibrant discussions, providing a platform for researchers and authors to showcase their work. The GGSCCD2025 meeting brings together world-class participants and promising young researchers, fostering opportunities for interdisciplinary exchanges that transcend traditional boundaries. This unique venue enables the resolution of complex multidisciplinary challenges. Attendees will have the chance to share and explore state-of-the-art developments and cutting-edge technologies in the expansive fields of Cardiology and Cardiovascular diseases.
We believe this gathering will be an exceptionally rewarding educational and collaborative experience for all attendees.
We eagerly anticipate your valuable presence at GSCCD2025 in Barcelona, Spain.
Arteriosclerosis, Thrombosis and Vascular Biology
Cardiac Electrophysiology
Cardiac Nursing: Acute and Chronic Cardiac Care
Cardio-Oncology and Nuclear Cardiology
Cardiopulmonary Rehabilitation and Prevention
Cardiovascular Diseases and Disorders
Cardiovascular Engineering and Technology
Cardiovascular Imaging and Image Analysis
Cardiovascular Pharmacology
Cardiovascular Translational Research
Cerebral Blood Flow and Metabolism
Circulation: Arrhythmia and Electrophysiology
Clinical and Experimental Cardiology
Current Research and Advances in Cardiology
Echocardiography
Cardiac CT and MRI
Genetics of Heart & Vascular Disease
Geriatric Cardiology
Heart Failure and Myocardial infarction
Heart Transplantation
Hypertension and Obesity
Interventional Cardiology and Radiology
Microvascular Deseases & problems
Congenital Heart Disease
Microcirculation and Inflammation
Molecular and Cellular Cardiology
Cardiopsychology
Nephrocardiology
Paediatric and Congenital Cardiovascular Disease
Preventive Cardiology
Resuscitation and Emergency Infusions
Stem Cell Research and Regeneration on Cardiology
Thoracic and Cardiovascular Surgery
Womens Cardiovascular Health: Cardiac Problems during Pregnancy,
Cardiovascular Angiography
Spain's
cardiovascular disease therapeutics market size is at around $3.13 Bn in 2022 and is projected to reach $5.08 Bn in 2030,
exhibiting a CAGR of 6.22% during the forecast period. The budget allotted to
the Ministry of Health in 2023 will rise by 6.5%, totaling $3,320 Mn, in the
setting of a decentralized healthcare system where spending by the Spanish
Ministry of Health accounts for less than 3% of total government spending. The
allocation of money from both the national public budget for 2023 and the
European Recovery and Resilience Facility are included in this sum. Notably,
$3.42 Mn and $4.49 Mn are allotted to the newly established nationwide Public
Health Agency and the nationwide network for public health surveillance,
respectively. The coordinated purchase of the COVID-19 vaccine is also
allocated $1,408 Mn. Finally, the Ministry of Health has budgeted more than
$1,284 Mn to improve primary care facilities and tools for specialized care,
screening programs, and mental healthcare. This money has been specifically
designated for the development of primary care. The autonomous towns will
receive this funding.
Adults from lower socioeconomic classes in Spain have a
significant prevalence of cardiovascular disease (CVD) risk factors. Although
immigrants are a socioeconomically disadvantaged group, little is known about
how these factors are distributed among them. The latest WHO statistics show
that 51,684 deaths from coronary heart disease, or 15.64% of all deaths,
occurred in Spain in 2020. Spain places #179 in the world with a 34.87 per
100,000 population age-adjusted death rate.
Therapeutic lifestyle changes, such as increased physical
exercise, dietary modification/weight loss, and quitting smoking are of proven
benefit and better outcomes starting within a matter of weeks for all of these
high-risk patients. Statins and aspirin are two additional adjunctive drug
treatments with a history of success; their advantages are at the very least
additive.
Best regards
Maya
GSCCD2025
Groups of three or more will receive a Special discount by using the group code. If you have any queries, please contact us at or call
gsccd@apexglobalmeetings.com